1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
62350413D7076B0B4002585A6003E75DE
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/db-skyrizi-case-study-developing-early-comparative-effectiveness-outcomes-studies-lift-launch-uptake-curve-accelerate-planned-obsolescence-abbvie-blockbuster?opendocument
18
19opendocument
203.237.186.116
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




Products & Services Product Launch Product Launch Excellence

Skyrizi Case Study: Developing Early Comparative Effectiveness and Outcomes Studies to Lift Launch Uptake Curve & Accelerate Planned Obsolescence of AbbVie’s Own Blockbuster

ID: 5625


Features:

6 Info Graphics

7 Data Graphics

100+ Metrics


Pages/Slides: 14


Published: 2020


Delivery Format: Online PDF Document


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from “Skyrizi Case Study: Developing Early Comparative Effectiveness and Outcomes Studies to Lift Launch Uptake Curve & Accelerate Planned Obsolescence of AbbVie’s Own Blockbuster”

STUDY OVERVIEW


While most drug manufacturers focus on extending the commercial life of their mega brands upon loss of patent exclusivity, AbbVie adopted an innovative strategy to replace its own $20 billion blockbuster immunology franchise with multiple products stronger in each indication.


With AbbVie’s Humira approaching the end of its patent exclusivity in 2023, AbbVie began executing its “planned obsolescence” strategy much earlier to replace Humira with an array of superior immunology drugs. Skyrizi initiated AbbVie’s franchise replacement strategy targeting Humira’s plaque psoriasis indication where it demonstrated superiority with its early comparative effectiveness and outcomes studies.

This case study reviews how AbbVie used early comparative effectiveness and outcomes to lift Skyrizi’s launch uptake curve and accelerate planned obsolescence of its own blockbuster Humira. It also examines AbbVie’s long term strategy targeting additional indications using comparative effectiveness and outcomes to further expand its immunology portfolio.


KEY TOPICS

  • AbbVie’s Lifecycle Strategy for its Immunology Franchise
  • Humira’s Planned Obsolescence
  • Skyrizi’s Comparative Effectiveness Dimension
  • Portfolio Approach to Clinical Trials
  • Long Term Strategy to Extend Skyrizi’s Market Foothold
  • Franchise Strategy

KEY METRICS
  • Timeline of Skyrizi
  • Number of comparator studies conducted across regions and indications to evidence Skyrizi’s effectiveness
  • Skyrizi’s test results in treating psoriasis against 5 competitor drugs at week 16
  • Global Skyrizi sales
  • Skyrizi’s test results in treating additional indications using comparative effectiveness
  • Additional comparator and outcomes studies

SAMPLE KEY FINDINGS
  • Go Head To Head With Market Leaders: Motivated by Humira’s upcoming patent expiration, Skyrizi developed comparator studies head to head against Humira and other market leaders as part of its launch strategy.


METHODOLOGY

This study was developed using extensive secondary research.


Industries Profiled:
Pharmaceutical


Companies Profiled:
AbbVie

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.